Immunogenicity of Polyethylene Glycol (PEG)
Author:
Open Access
- 3 October 2011
- journal article
- Published by Bentham Science Publishers Ltd. in The Open Conference Proceedings Journal
- Vol. 2 (1) , 104-107
Abstract
Covalent attachment of polyethylene glycol (PEG) to active proteins (PEGylation technology) successfully generated several FDA-approved compounds, including four blockbusters, which are considered non immunogenic. However, PEG antibodies and intolerance to the infusion were reported in some patients with gout treated with pegloticase, a PEG-uricase recently approved by the FDA (Food and Drug Administration, USA). Therefore, we reviewed the literature concerning immunogenicity of PEG alone or covalently attached to proteins. We consulted databases (Scirus, Pub Med, Cochrane Library, and Science Direct) and the references of selected articles and main journals publishing articles on the subject. Animal studies clearly showed that PEG-uricases and some other PEGylated proteins might elicit antibody formation against PEG. This anti-PEG response can accelerate the clearance of PEGylated proteins. Of major importance is the recent finding of a 22%-25% occurrence of PEG antibodies in healthy blood donors. PEG antibodies may limit therapeutic efficacy and/or reduce tolerance of PEG-asparaginase (PEG-ASNase) in patients with acute lymphoblastic leukemia and of pegloticase in patients with chronic gout, but apparently do not impair hyposensitization of allergic patients with mPEG-modified ragweed extract and honey bee venom or the response to PEGinterferon in patients with hepatitis C. In conclusion, pre-existing or newly developed PEG antibodies may limit therapeutic efficacy and/or reduce tolerance of PEGylated proteins in some patients. The immunogenicity of PEGylated therapeutic agents in clinical use or development deserves to be reexamined by investigating PEG antibodies.Keywords
This publication has 22 references indexed in Scilit:
- 307 HIGH PREVALENCE OF PRE-EXISTING ANTIBODIES AGAINST POLYETHYLENE GLYCOL (PEG) IN HEPATITIS C (HCV) PATIENTS WHICH IS NOT ASSOCIATED WITH IMPAIRED RESPONSE TO PEG-INTERFERONJournal of Hepatology, 2010
- Characterization, stabilization and activity of uricase loaded in lipid vesiclesInternational Journal of Pharmaceutics, 2010
- Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent processMolecular Immunology, 2008
- PEG-uricase in the management of treatment-resistant gout and hyperuricemiaAdvanced Drug Delivery Reviews, 2008
- Antibody against poly(ethylene glycol) adversely affects PEG‐asparaginase therapy in acute lymphoblastic leukemia patientsCancer, 2007
- Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomesJournal of Controlled Release, 2007
- PEGylation, successful approach to drug deliveryDrug Discovery Today, 2005
- Studies on antigenicity of the polyethylene glycol (PEG)-modified uricaseInternational Journal of Immunopharmacology, 1985
- Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol.Journal of Biological Chemistry, 1977
- Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase.Journal of Biological Chemistry, 1977